The startup specializes in radioligand therapy that utilizes alpha and beta emitters to disrupt cancer cell DNA, optimizing peptide ligand vectors for the development of theranostic agents. This approach provides medical practitioners with targeted treatment options that enhance the efficacy of oncology therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Targeted cancer therapies often lack the precision to selectively destroy cancer cells while sparing healthy tissue, leading to significant side effects. Traditional radiation therapies can damage surrounding organs, and systemic chemotherapies can cause widespread toxicity.
Solution
This startup develops radioligand therapies that deliver targeted radiation directly to cancer cells, minimizing damage to healthy tissue. They optimize peptide ligand vectors to selectively bind to receptors overexpressed on cancer cells. These vectors are linked to alpha or beta-emitting radioisotopes, which disrupt cancer cell DNA upon binding. This approach enables the creation of theranostic agents, allowing for both diagnostic imaging and targeted treatment of cancer.
Target Audience
The primary target audience includes medical practitioners, oncologists, and hospitals seeking more effective and targeted cancer treatment options.
Features
- Peptide ligand vectors engineered for high affinity and specificity to cancer cell receptors
- Use of alpha and beta-emitting radioisotopes for potent and localized cell killing
- Theranostic capabilities, enabling both diagnostic imaging and targeted therapy with the same agent
- Optimized for various cancer types based on receptor expression profiles